Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

[1]  J. Ouyang,et al.  Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia , 2013, PloS one.

[2]  J. Beyene,et al.  Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysis , 2013, British journal of haematology.

[3]  H. Dombret,et al.  Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Chevallier,et al.  Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. , 2012, Blood.

[5]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[6]  Augustin Ferrant,et al.  Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.

[7]  T. Naoe,et al.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.

[8]  M. Bernard,et al.  Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial , 2010, Leukemia.

[9]  J. Bennett,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[10]  M. Vignetti,et al.  Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[12]  J. Rowe.  Optimal induction and post-remission therapy for AML in first remission. , 2009, Hematology. American Society of Hematology. Education Program.

[13]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[14]  T. H. A. C. O. G. Roup.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998 .

[15]  R. Peto,et al.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998, British journal of haematology.

[16]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .